Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q4 EPS of ($0.55), $0.01 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.